What's Happening?
The FDA has approved Celcuity's kinase inhibitor, gedatolisib, branded as Revtorpyk, for the treatment of certain patients with locally advanced or metastatic breast cancer. This approval marks Celcuity's entry into the commercial market with its first
product. Revtorpyk is indicated for use in combination with AstraZeneca's Faslodex, with or without Pfizer's Ibrance, specifically targeting patients with HR-positive, HER2-negative breast cancer without PI3KCA mutations. The approval provides Celcuity with a unique position in the breast cancer treatment landscape, differentiating it from other PI3K/AKT inhibitors that focus on PI3KCA mutation-positive patients.
Why It's Important?
The approval of Revtorpyk offers a new treatment option for a significant subset of breast cancer patients who do not have PI3KCA mutations. This expands the therapeutic arsenal available to oncologists and could improve outcomes for patients who have progressed on previous endocrine therapies. The differentiation of Revtorpyk from existing treatments like Novartis' Piqray and Gilead's Zydelig could lead to its rapid adoption in clinical practice, potentially altering standard treatment protocols for this patient population. The approval also underscores the importance of personalized medicine in oncology, where treatments are tailored to the genetic profile of the cancer.
What's Next?
Celcuity plans to launch Revtorpyk in the U.S. market in late Q3, accompanied by a comprehensive patient support program. The company will focus on the drug's market introduction and how well it is integrated into clinical practice. Additionally, Celcuity is preparing to file a supplemental package for Revtorpyk based on data from patients with PI3KCA mutations. The ongoing Phase 3 VIKTORIA-2 trial will further evaluate Revtorpyk as a first-line treatment option, potentially expanding its use to a broader patient population.
